Common Contracts
13 similar Employment Agreement contracts by Viridian Therapeutics, Inc.\DE, Signal Genetics, Inc., Miragen Therapeutics, Inc.
VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2024 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of January 10, 2024 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Jennifer Tousignant, an individual residing at 29 Wheelock Road, Sutton, MA 01590 (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referred to individually as a “Party”).
VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2024 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of January 12, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Thomas Ciulla, an individual residing at 15977 Bridgewater Club Blvd, Carmel, IN 46033 (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referred to individually as a “Party”).
VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2024 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of April 24, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Seth Harmon, an individual residing at 74 Chebacco Rd, Hamilton, MA 01982 (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referred to individually as a “Party”).
VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2024 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of May 11, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Lara Meisner, an individual residing at 11 Thornton Road, Needham, MA 02492 (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referred to individually as a “Party”).
VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 13th, 2023 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 27, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Thomas Beetham (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referred to individually as a “Party”).
VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • November 13th, 2023 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 27, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Steve Mahoney (“Executive”). (Executive and the Company collectively the “Parties” and each of the Parties referred to individually as a “Party”).
MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • January 20th, 2021 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • Massachusetts
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of January 15, 2021 (the “Effective Date”), is by and between miRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and Jonathan Violin, PhD (“Executive”).
MIRAGEN THERAPEUTICS, INC.EMPLOYMENT AGREEMENTEmployment Agreement • June 19th, 2020 • Miragen Therapeutics, Inc. • Services-medical laboratories • New York
This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of June 16, 2020 (the “Effective Date”), is by and between miRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and Lee Rauch (“Executive”).
MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2020 • Miragen Therapeutics, Inc. • Services-medical laboratories • Colorado
This EMPLOYMENT AGREEMENT, dated as of February 20, 2020 (the “Effective Date”), is by and between miRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and Diana Escolar (“Executive”).
MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 2nd, 2016 • Signal Genetics, Inc. • Services-medical laboratories • Colorado
This EMPLOYMENT AGREEMENT, dated as of December 2, 2016, is by and between MiRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and William S. Marshall, Ph.D. (“Executive”).
MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 2nd, 2016 • Signal Genetics, Inc. • Services-medical laboratories • Colorado
This EMPLOYMENT AGREEMENT, dated as of December 2, 2016, is by and between MiRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason A. Leverone (“Executive”).
MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 2nd, 2016 • Signal Genetics, Inc. • Services-medical laboratories • Colorado
This EMPLOYMENT AGREEMENT, dated as of December 2, 2016, is by and between MiRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and Paul D. Rubin (“Executive”).
MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 2nd, 2016 • Signal Genetics, Inc. • Services-medical laboratories • Colorado
This EMPLOYMENT AGREEMENT, dated as of December 2, 2016, is by and between MiRagen Therapeutics, Inc., a Delaware corporation (the “Company”), and Adam S. Levy (“Executive”).
